Centre for Medical Engineering Imaging Bioresource

• Research type

  Research Tissue Bank

• IRAS ID

  264346

• Research summary

  Centre for Medical Engineering Imaging Bioresource

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  20/LO/0036

• Date of REC Opinion

  9 Mar 2020

• REC opinion

  Further Information Favourable Opinion

• Data collection arrangements

  We seek to establish and run a specialist Bioresource for research into neurological, cancer and cardiovascular conditions. Medical images from patients using our imaging facilities along with clinical information and biological specimens will be collected. Source data include, but are not limited to, hospital records (from which medical history and previous and concurrent medication may be summarised into the Case Report Form), clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.
  When a patient has agreed to participate and have their clinical data, medical images and/or biological samples retained as part of the Research Tissue Bank, the participant/parent/legal guardian or legally authorised representative will be asked to sign and date the latest approved version of the Research Tissue Bank Informed Consent Form (ICF) before any study specific procedures are performed. It will be clearly stated in the patient information sheet that the participant is free to withdraw their participation in the research tissue bank at any time and have their data/samples destroyed, for any reason without prejudice to future care, without affecting their legal rights, and with no obligation to give the reason for withdrawal.

• Research programme

  The primary aim of the tissue bank is to provide a resource of clinical data, clinical images (e.g. MRI) and biological samples (including but limited to blood, saliva, tissue) to be used in clinical research to address research questions including but not limited to the following: • Improving long-term neurological outcomes and developing biomarkers to stratify and optimise treatment in neuropsychiatric disease. • Improving outcomes of patients with chronic cardiac conditions, particularly structural and ischaemic heart disease, heart failure and cardiac arrhythmias. • Improving the care of patients with cancer with better stratification and improved treatment selection, as well as identifying ineffective treatments early so they can be changed.

• Storage license

  12522

• RTBTitle

  Centre for Medical Engineering Imaging Bioresource

• Establishment organisation

  King's College London

• Establishment organisation address

  St Thomas' Hospital

  London

  SE1 7EH